Literature DB >> 23845563

Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype.

Michael E Henry1, Tara L Lauriat, Steven B Lowen, Jeffrey H Churchill, Colin A Hodgkinson, David Goldman, Perry F Renshaw.   

Abstract

This study was designed to assess whether functional magnetic resonance imaging (fMRI) following antidepressant administration (pharmaco-fMRI) is sufficiently sensitive to detect differences in patterns of activation between enantiomers of the same compound. Healthy adult males (n=11) participated in a randomized, double-blind, cross-over trial with three medication periods during which they received citalopram (racemic mixture), escitalopram (S-citalopram alone), or placebo for 2 weeks. All participants had high expression serotonin transporter genotypes. An fMRI scan that included passive viewing of overt and covert affective faces and affective words was performed after each medication period. Activation in response to overt faces was greater following escitalopram than following citalopram in the right insula, thalamus, and putamen when the faces were compared with a fixation stimulus. For the rapid covert presentation, a greater response was observed in the left middle temporal gyrus in the happy versus fearful contrast following escitalopram than following citalopram. Thus, the combination of genomics and fMRI was successful in discriminating between two very similar drugs. However, the pattern of activation observed suggests that further studies are indicated to understand how to optimally combine the two techniques.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Affective stimulus; Antidepressant; Functional magnetic resonance imaging; Imaging genetics; Pharmaco-fMRI

Mesh:

Substances:

Year:  2013        PMID: 23845563      PMCID: PMC4681447          DOI: 10.1016/j.pscychresns.2013.05.008

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  42 in total

1.  Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study.

Authors:  Y I Sheline; D M Barch; J M Donnelly; J M Ollinger; A Z Snyder; M A Mintun
Journal:  Biol Psychiatry       Date:  2001-11-01       Impact factor: 13.382

2.  Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI.

Authors:  K Luan Phan; Tor Wager; Stephan F Taylor; Israel Liberzon
Journal:  Neuroimage       Date:  2002-06       Impact factor: 6.556

3.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

4.  Functional connectivity in the resting brain: a network analysis of the default mode hypothesis.

Authors:  Michael D Greicius; Ben Krasnow; Allan L Reiss; Vinod Menon
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-27       Impact factor: 11.205

Review 5.  Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.

Authors:  P E Cole; A J Schwarz; M E Schmidt
Journal:  Clin Pharmacol Ther       Date:  2012-01-04       Impact factor: 6.875

Review 6.  Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.

Authors:  Stefano Porcelli; Chiara Fabbri; Alessandro Serretti
Journal:  Eur Neuropsychopharmacol       Date:  2011-12-03       Impact factor: 4.600

7.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

8.  Serotonin transporter genetic variation and the response of the human amygdala.

Authors:  Ahmad R Hariri; Venkata S Mattay; Alessandro Tessitore; Bhaskar Kolachana; Francesco Fera; David Goldman; Michael F Egan; Daniel R Weinberger
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Increased amygdala responses to sad but not fearful faces in major depression: relation to mood state and pharmacological treatment.

Authors:  Danilo Arnone; Shane McKie; Rebecca Elliott; Emma J Thomas; Darragh Downey; Gabriella Juhasz; Steve R Williams; J F William Deakin; Ian M Anderson
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

10.  Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.

Authors:  B R Godlewska; R Norbury; S Selvaraj; P J Cowen; C J Harmer
Journal:  Psychol Med       Date:  2012-04-25       Impact factor: 7.723

View more
  4 in total

Review 1.  The Insula: A "Hub of Activity" in Migraine.

Authors:  David Borsook; Rosanna Veggeberg; Nathalie Erpelding; Ronald Borra; Clas Linnman; Rami Burstein; Lino Becerra
Journal:  Neuroscientist       Date:  2015-08-19       Impact factor: 7.519

2.  Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation.

Authors:  Milan Scheidegger; Anke Henning; Martin Walter; Mick Lehmann; Rainer Kraehenmann; Heinz Boeker; Erich Seifritz; Simone Grimm
Journal:  Hum Brain Mapp       Date:  2016-02-25       Impact factor: 5.038

3.  Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study.

Authors:  Henk Cremers; Royce Lee; Sarah Keedy; K Luan Phan; Emil Coccaro
Journal:  Neuropsychopharmacology       Date:  2015-06-24       Impact factor: 7.853

4.  Modulation of premotor cortex response to sequence motor learning during escitalopram intake.

Authors:  Eóin N Molloy; Karsten Mueller; Nathalie Beinhölzl; Maria Blöchl; Fabian A Piecha; André Pampel; Christopher J Steele; Ulrike Scharrer; Gergana Zheleva; Ralf Regenthal; Bernhard Sehm; Vadim V Nikulin; Harald E Möller; Arno Villringer; Julia Sacher
Journal:  J Cereb Blood Flow Metab       Date:  2020-11-04       Impact factor: 6.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.